2nd Quarter - Report

PRIME THERAPEUTICS for PRIME THERAPEUTICS

Firm
Client
Income
—
Expenses
$80,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Education on the value of biosimilars; HR 19/S 2164-Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing and Part D reform; HR 3-Elijah E. Cummings Lower Drug Costs Act Now, provisions establishing drug pricing and Part D cost sharing; value-based contracting for pharmaceuticals; H.R. 5376, Build Back Better Act, provisions relating to insulin cost-sharing; repeal of the rebate rule and audit/transparency provisions on PBMs; S. 3700/H.R. 6833, Affordable Insulin Now Act, provisions related to cost-sharing for insulin in Medicare and private plans and 116th Congress H.R. 2069; draft versions of the INSULIN Act, provisions on cost-sharing, utilization management and rebates for insulin; S. 4293 The Pharmacy Benefit Manager Transparency Act of 2022, provisions on the FTC regulation of PBMs and S. 1388, Prescription Pricing for the People Act of 2021, provisions related to an FTC study of PBMs; provisions related to restrictions on spread pricing in the commercial market for PBMs, and HR. 4390, Protect 430(b) Act of 2021, provisions related to the treatment of 340(b) drug discount program by PBMs.

LobbyistCovered position, as disclosed
JULIE CAROL CANTOR-WEINBERG —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 1388 (117th), H.R. 19 (117th), S. 4293 (117th), S. 3700 (117th), H.R. 3 (117th), H.R. 2069 (117th), H.R. 6833 (117th), H.R. 4390 (117th), H.R. 5376 (117th)

Medicare/Medicaid MMM

Final Rule, Department of Health and Human Services: Office of Inspector General, issued November 20, 2020 entitled Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Services Fees; outreach on pharmacy direct and indirect remuneration in Medicare Part D and CMS-4192-P, Proposed and Final Rules, Medicare Program: Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Program;" HR 19/S 2164-Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing and Part D reform; HR 3-Elijah E. Cummings Lower Drug Costs Act Now, provisions establishing drug pricing and Part D cost sharing; value-based contracting for pharmaceuticals; H.R. 5376, Build Back Better Act, provisions relating to insulin cost-sharing; Medicaid and Medicare drug pricing; Medicare Part D reform, repeal of the rebate rule and audit/transparency provisions on PBMs; S. 3700/H.R. 6833, Affordable Insulin Now Act, provisions related to cost-sharing for insulin in Medicare and private plans and mental health issues as they relate to prescription drug plans; draft versions of the INSULIN Act, provisions on cost-sharing, utilization management and rebates for insulin.

LobbyistCovered position, as disclosed
JULIE CAROL CANTOR-WEINBERG —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: H.R. 6833 (117th), H.R. 5376 (117th), S. 3700 (117th), H.R. 19 (117th), H.R. 3 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.